provided significantly higher (P < 0.001) radioactivity levels. in the brain, but neither EDU, 2 or 3 protected mice against intracerebral herpes simplex virus infection. Hepatic uptakes of 2, 3 and 4, in mice, were similar to each other despite the respective substantial increases in both molecular weight and lipophilicity of this series. In rats, biliary excretion over the 0-4 h period after l.v, injection accounted for only 2.9-3.9% of the injected dose for these prodrugs.
Summary
(+)-Trans-(SR,6R)- S-bromo-S-ethyl-6-ethoxy-S,6-dihydro-S'-Q-valeryl-2'-deoxy-uridine (3) and (+)-trans-(SR,6R)-S-bromo-S-ethyl-6-ethoxy-S,6-dihydro-3',S'-di-Q-valeryl-2'-deoxyuridine (4) were synthesized in SS% and 8.6% yield, respectively, by esterification of the S'hydroxyl group of (+)-trans-(SR,6R)-S-bromo-S-ethyl-6-ethoxy-S,6-dihydro-2'-deoxyuridine (2) using valeryl chloride. [4_ 14C]_3 and [4_ 14C]_4 were synthesized in 79% and 64% chemical and radiochemical yield, respectively, by similar esterifications of [4_ 1 4C]_2.
The double prodrug 3 was readily hydrolysed (> 9S% in 8 min) to S-ethyl-2'-deoxyuridine (EDU) by porcine liver esterase in vitro. The biotransformations of 2 and 3 were studied following Lv. injection of a 0.4 mmoJlkg l.v, dose to male Salb/c mice. The single prodrug 2 was rapidly cleared «10 min) from the blood. The area under the blood concentration-time curve (AUC) for EDU, as a metabolite of 2, was higher (2.1 ± 0.4 umol.h.q'") than the AUC observed when EDU itself was injected (1.7 ± 0.2 umol.h.q"). The double prodrug 3 provided a sustained high concentration of EDU in blood, with an AUC for EDU, as a metabolite of 3, of 1.8 ± 0.2 umol.nr.q:". S'-Q-Valeryl-Sethyl-2'-deoxyuridine and 3 were both detected in blood samples collected up to 3Smin post l.v. injection. S-Ethyluracil and S-(l-hydroxyethyl)-uracil were identified as secondary metabolites of EDU, 2 and 3.
Dedication
This work is dedicated to Professor Dr. Richard Neidlein, Professor of Pharmaceutical Chemistry, Heidelberg Universitat, Heidelberg, Germany, on the occasion of his 65th birthday, in recognition of an outstanding career.
Introduction 5-Ethyl-2'-deoxyuridine (EDU, 1, Fig. 1 ) is a selective antiherpetic agent that is phosphorylated by herpes simplex virus-encoded thymidine kinase (HSV-TK), but not by mammalian TK (Bernaerts and De Clercq, 1987) . EDU has antiviral activity against several strains of HSV (De Clercq and Shugar, 1975; Teh and Sacks, 1983) and is an effective, non-mutagenic antiviral agent for the treatment of topical HSV infections (Swierkowski and Shugar, 1969) . It has been reported to increase the survival time of mice with HSV encephalitis (HSE) (Davis et al., 1979) but it is not approved for this use clinically. EDU has some undesirable properties, including rapid elimination after i.v. administration, rapid enzymatic degradation to nonvirostatic metabolites [5-ethyluracil and 5-(1-hydroxyethyl)uracil] (Buchele et el., 1989; Kaul and Hempel, 1985) and low lipophilicity (Cheraghali et al., 1994a ) that may limit its passage across the blood-brain-barrier.
Herpes simplex encephalitis (HSE), a severe brain infection, is associated with high mortality and morbidity when untreated. It has been estimated that the incidence of HSE ranges from two to four per million population per year, with approximately 30% occurring during childhood (Cameron et et., 1992) . Although antiherpetic drugs (e.g. aciclovir) are now available for therapy (Skoldenberg, 1991) and new drugs are being evaluated, efficacy for treatment of encephalitis may still be limited by sub-therapeutic concentrations of the antiviral nucleoside in the brain.
It was previously reported that cephalic delivery of EDU could be improved by using a lipophilic 5,6-dihydro-EDU prodrug (Cheraghali et al., 1994a (Cheraghali et al., , 1994b . This 5,6-dihydro prod rug approach has been used to improve the efficacy of and/or alter the pharmacokinetic parameters of pyrimidine nucleoside drugs such as 5-f1uoro-2'-deoxyuridine (Duchinsky et al., 1967) , 5-f1uorouracil (Visser et al., 1989) , 3'-azido-3'-deoxythymidine and EDU (Cheraghali et sl., 1994a (Cheraghali et sl., , 1994b . However, there is need for further improvement in cephalic delivery of this important class of drugs.
Hydroxyl group esterification is frequently used to improve the in vivo efficacy of nucleosides. Ganciclovir (Powell et al., 1991) , 5-iodo-2'-deoxyuridine (Keppler et el., 1984) and EDU (Cheraghali et el., 1994a) are representative examples of this approach. However, since it is often difficult to design simple, effective prod rugs, the double prod rug concept (prod rug of a prod rug) has been proposed as a potential method to overcome some of the limitations that maybe associated with common prodrugs, as in the case of acyclovir (Bundgaard, 1989) .
The synthesis of (+)-trans-(5R,6R)- 5-bromo-5-ethyl-6ethoxy-5,6-dihydro-5 
4, their selected in vitro properties and their brain uptake and hepato-biliary excretion in vivo are now reported. In this series, 2 is a simple prod rug of 1, 3 is a double prodrug and 4 is a triple prodrug, by sequential incorporation of the 5,6-dihydro substiutents, the primary ester and the secondary ester, respectively ( Fig. 1.) .
Results
Reaction of (+)-trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-2'-deoxy-uridine (2) with valeryl chloride (1.72 equivalents) in dry pyridine at 25°C afforded a mixture of the 5'-O-valerate (3, 55%) and 3',5'-di-O-valerate (4, 8.6%) esters which were separated by silica gel column Double prodrugs of 5-ethyldeoxyuridine 357 chromatography. A similar reaction of [4_ 14C]-2 with valeryl chloride in the presence of EtsN at 25°C for 30 min afforded [4_ 14C]-3 in 97% chemical and radiochemical yield [>96% radiochemical purity after preparative HPLC purification, specific activity 2GBq (54mCi)mmol-1j. When the same reaction was performed using a larger amount of valeryl chloride at 25°C for 2 h, [4_ 14C]-4 was isolated in 64% chemical and radiochemical yield [>98% radiochemical purity after preparative HPLC purification, specific activity 2GBq (54mCi)mmol-1j.
An efficient quantitative HPLC analytical procedure was developed to separate 3 and its metabolites in blood samples. The previously reported HPLC procedure provided good separation of 5,6-dihydro prodrugs of EDU, EDU and its metabolites (Cheraghali et al., 1994a) , but separation of 3 and its metabolites required a more complex gradient of acetonitrile and water, in combination with a flow rate gradient. This new HPLC procedure provided excellent baseline separation of 3 and its metabolites in blood. Quantitative HPLC data were used to calculate the pharmacokinetic parameters and to elucidate the mechanisms responsible for activation of 3 in vivo.
Rapid enzymatic hydrolysis of 3 to 2 upon incubation with porcine liver esterase at 37°C «95% converted after an 8 min incubation) agrees closely with the reported facile enzymatic hydrolysis of 5'-O-valeryl-2'-deoxyuridine (Ghosh and Mitra, 1991) . No chemical hydrolysis of 3 was observed in a control experiment under incubation conditions but without the enzyme.
The mean concentration-time profiles of EDU, 2 and 3 in mice which received a 0.4 mmol kg-1 i.v. dose of the test compound are shown in Fig. 2 . The 5,6-dihydro prodrug 2 had a very short « 10 min) blood residence time, but afforded a high concentration of EDU in blood due to its rapid biotransformation to EDU. The area under the blood concentration vs time curve (AUG) for EDU after injection of 2 was about 23% higher (2.1±0.4llmol.h.g-1 ) than that observed when EDU was injected (1.7±0.2 urnol.h.q") ( 
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The double prodrug 3 produced a sustained, high concentration of EDU in blood following i.v, injection. The AUC for EDU, as a metabolite of 3, was similar to that of EDU when EDU itself was injected (1.8±0.2 umot.h.q"), and substantlatly lower than the AUC of EDU after injection of 2. 5-Ethyluracil and 5-(1-hydroxyethyl)uracil were detected as secondary metabolites of· EDU, 2 and 3 ( Fig. 3) . The concentration of ethyluracil in blood samples after injection of 2 was higher than the concentrations of ethyl uracil after injection of EDU or 3 (Table 1) . In contrast to 2, which could not be detected 10 min after injection, 3 and 5'-O-valeryl-5-ethyl-2'-deoxyuridine were detected in blood samples collected up to 35 min later.
Biodistribution studies in mice showed radioactivity levels in blood and liver to be similar, and much higher than in the brain after i.v. injection of [4-14C]-labelled EDU, 2, 3 and 4, respectively ( Fig. 4 ). Clearance of radioactivity from blood and liver after injection of [4-14C]-EDU was substantially faster than after [4_ 14C]-2, .The radioactivity levels in brain samples taken after injection of [4_ 14C]-3 and [4_ 14C]_4 were significantly higher (P<0.001) than after [4-14C]-EDU. In a series of experiments in the rat, a species that is well characterized as proficient in both biliary excretion and hepato-biliary recirculation of xenobiotics, the biliary excretion of these products was surprisingly, found to +/-0.1, 3.2+/-0.8 and 2.9+/-0.1 percent of injected dose for 2, 3 and 4, respectively. EDU, 2 and 3 failed to protect NMRI mice innoculated intracerebrally with HSV-1 or HSV-2 in an experiment in which aciclovir protected 40% and 60% at daily doses of 0.22 and 0.89 mmol kg-1 day", respectively. In in vitro studies against several strains of HSV in Hela cells (Tablez) these compounds were much less potent than either acyclovir or bromovinyldeoxyuridine. Overall the anti-HSV potency and activity spectra for 2 and 3 were similar to that of EDU. 
Discussion
Novel 5-ethyl-5-haI0-6-alkoxy-5,6-dihydro prod rugs of EDU were recently synthesized and evaluated in vitro and in vivo studies (Cheraghali et al., 1994a (Cheraghali et al., , 1994b . Complex (double and triple) prodrugs to EDU have now been developed to further improve the delivery characteristics and therapeutic efficacy of EDU. The double prodrug was designed to have two distinct mechanisms for regeneration of EDU:one activation mechanism was designed to in mice. Data are presented as the mean ± SEM (n=3).
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:j: Concentration required to reduce cell growth by 50% after 3 days of incubation. § Minimum cytotoxic concentration that causes a microscopically detectable alteration of normal cell morphology after 2 days of incubation.
proceed via enzymatic hydrolysis of a primary ester, and the second would procede via non-enzymatic regeneration of the S,6-0Iefinic bond. In the triple prodrug a secondary ester was added to modulate the rate of de-esterification. It was not possible to predict whether regeneration of EDU would involve a fixed cascade in which one of these mechanisms would always preceed the other. Valerie acid was selected for esterification of the S'-hydroxyl group on the basis of a report that the S'-O-valeryl ester has a very short half-life upon incubation with rat plasma, that it is more lipophilic than other S'-Oaliphatic esters of S-iodo-2'-deoxyuridine (Ghosh and Mitra, 1991) and that S'-O-valeryl-EDU has antiviral activity similar to that of EDU, presumably due to its rapid conversion to EDU (Keppler et al., 1986) . S'-O-Valeryl-EDU (a metabolite of 3) has a P value of 1.6 (Keppler et el., 1986) , slightly higher than that for 2 (P=1.1). Since it was previously observed that 2 crosses the BBB at a significantly higher (P < O.OS) level than EDU (Cheraghali et el., 1994b) , it was anticipated that S'-O-valeryl-EDU would also enter the brain at levels comparable to 2. Valeryl ester formation at the 3'-hydroxyl produced the triple prodrug. The single prodrug 2 has a substantially higher octanol/buffer partition coefficient (P=1.1) than EDU (P=0.08). Masking the S'-hydroxyl group of 2 with a valeryl group to make the double prodrug 3 increased the Iipophilicity by an additional log order (P=11.S) (Table 1) , and introduction of the second valeryl ester at 3'increased the lipophilicity beyond the capacity of the measurement system used. It has been reported that increasing the Iipophilicity of compounds with a molecular weight of about 400 enhances their ability to permeate the brain (Levin, 1980) . In the absence of an active transport system, the enhanced Iipophilicity of these EDU prodrugs should therefore facilitate their diffusion across the blood-brain-barrier (BBB). Although the prodrugs would also diffuse out of the cell at the same rate at which they diffuse into the cell, rapid regeneration of the 5,6-0Iefinic bond and/or enzymatic hydrolysis of the ester moiety would effectively trap the more polar antiviral (EDU)compound/single prodrug. Phosphorylation of EDU by HSV-TK+ in virus-infected cells (metabolic trapping) would then result in higher concentrations of antiviral drug than would have been attained without the prodrug.
Compared to [4-14C]-EDU, [4_ 14C]-2 produced significantly higher (P < O.OS) brain radioactivity levels after l.v, injection into mice (Cheraghali et a/., 1994a) . It was therefore expected that [4_ 14Cj-3, which has a P value one-log order larger than 2, would produce even higher brain radioactivity concentrations. Indeed, injection of [4_ 14Cj-3 provided significantly higher (P < 0.001) radioactivity levels in brain samples compared to levels after injection of There are no reported data known regarding the effective range of concentrations of pyrimidine nucleoside antlvlrals achieved in vivo in brain for treatment of HSE, so even though the present data indicate that 3 and 4 cross the BBB more readily than either EDU or 2, it is not possible to say whether or not the temporary increases would actually improve the therapeutic outcome. Unfortunately, the weak activity of all of these EDU series prodrugs does not contribute to the development of a clinically-useful result. There was no substantial difference in radioactivity levels in brain samples taken at 3 min or later post-injection of [4_ 14Cj_3, compared to radioactivity levels after injection of [4_ 14C]-4. This indicates that beyond a certain lipophilicity of the prodrugs (e.g. from 3 to 4) there will not be any increase in delivery to the brain. The consistently higher radioactivity levels in brain samples taken after injection of [4_ 14C]-3 relative to those for [4-14Cl-EDU (Fig. 3) suggest that the prodrug 3 indeed undergoes conversion to EDU. This conversion would decrease efflux from the brain because of EDU's lower lipophilicity, a phenomenon that would support the hypothesis behind the development of these prod rugs. Trapping the prod rug 4 by this process could involve all 3 unique rate-dependent processes (e.g. elimination of the 5,6-dihydro functionality to form the pyrimidine nucleus, and hydrolysis of both primary and secondary ester groups of the sugar moiety). Unfortunately, given the low concentrations actually present in the brain, it was not possible to determine the chemical nature of the radioactive species present. Based on the comparisons of 3 to 4, there does not appear to be any additional advantage to invoking the second hydrolysis step (triple prodrug).
The average blood concentration-time profiles for these studies are shown in Fig.2 . These pharmacokinetic studies were based on therapeutic doses, thereby facilitating HPLC analysis which showed that EDU was rapidly metabolized to 5-ethyluracil and then in turn, hydroxylated to form 5-(1-hydroxyethyl)uracil. Single prodrug 2 had a very short half-life following i.v, injection; it could not be detected in blood samples collected 10 min after injection, but its first metabolite (EDU) was present in high concentration in blood. Therefore, the rapid clearance of 2 from blood is due, at least in part, to its rapid conversion to EDU.
The double prod rug 3 provided a consistent but lower concentration of EDU in blood following l.v. injection into mice than observed for 2, thereby providing the desired pharmacokinetic effect. The prodrug (3) itself and 5'-0valeryl-EDU (the 5,6-dihydro elimination product) were detected in blood samples collected up to 35 min postinjection. This observation indicates that the t 1 / 2 for 3 was longer than might be predicted on the basis of in vitro esterase incubation experiments. In contrast to 2, which could not be detected 10 min after injection, the persistence of 5'-0-valeryl-EDU in blood samples support the conclusion that 5,6-dihydro elimination occurs much more rapidly than primary-ester hydrolysis in vivo. It can be inferred that the 5,6-dihydro functionality influences the biodistribution and clearance of the the active species (Le. EDU) for only a short period after injection of these prodrugs.
Since radioactivity levels in murine liver after injection of the [4-1 4Cl-labelled prodrugs were essentially mimicing blood levels, it was apparent that biliary excretion was unlikely to playa substantial role in clearance of the prod rugs and/or their metabolites. The rapid Double prodrugs of 5-ethyldeoxyuridine 361 regeneration of the 5,6-double bond of these prodrugs may account for their transient, low hepatic uptake and insignificant biliary excretion, as well as for the very small differences in these parameters within the series of prod rugs. The very small radioactivity content in rat bile after i.v, doses of the radiolabelled prod rugs confirmed the relatively minor role of hepatic clearance. of these compounds. It is surprising that Iipophilicity (range log P of 0.04-»1.1) and molecular weight (range 367-549 daltons) had little influence on the hepatobiliary uptake and clearance of these compounds, since both properties are generally accepted as predictors of hepatobiliary clearance (Tse et al., 1978) . These prod rugs have only low protein binding (in the range of 10-20% compared to 7% for EDU, by bovine serum albumin), so it is unlikely that any substantial effect could be attributed to this phenomenon.
A plausible mechanism for activation of 3 is shown in Fig. 3 . In this biotrans-formation pathway, 3 is converted into 2 and 5'-0-valeryl-EDU simultaneously (k 1 , k 2 ) , and 2 and 5'-0-valeryl-EDU are subsequently converted to EDU, by regeneration of the s.s-oleflnlc bond (2) and hydrolysis of 5'-0-valeryl-EDU, respectively (k s , k 4 ) . The increased residence time of 5'-0-valeryl-EDU in blood samples compared to 2 confirms that in vivo regeneration of the 5,6-0Iefinic bond occurs at a rate much faster than enzymatic hydrolysis of the 5'-0-ester (k s»k4 ) .
Although previously reported data showed efficacy for EDU against HSE (Davis et sl., 1979) , neither EDU or these prod rugs (2 and 3) were able to protect NMRI mice inoculated intracerebrally with HSV-1 and HSV-2 (Table  3) in the studies carried out by this paper. The inability of 2 or 3 to protect mice against HSE is most likely due to the fact that in these studies EDU itself, relative to aciclovir, was only weakly active against these strains of HSV in vitro.
In conclusion, this investigation has shown that i.v, injection of the 5,6-dihydro double/triple ester prod rugs of EDU into mice produces a transient improvement in the delivery of EDU into the brain. Blood clearance and hepatic clearance are directly linked to each other in this series, and biliary excretion represents only a small fraction of the injected dose for each of these compounds. Since neither EDU or these prodrugs protected mice that had been intracerebrally-innoculated with HSV, the in vivo efficacy of this complex prod rug concept remains unproven in terms of brain delivery. None-the-Iess, this pyrimidine nucleoside prodrug approach remains viable for improving the pharmacokinetic properties in vivo. Improvements can be expected in the efficacy of a number of other nucleosides that are active in vitro but have low in vivo efficacy because of poor bioavailability due to gastro-intestinal degradation, phosphorolytic cleavage of the glycosidic bond of the active nucleoside
Materials and Experimental Procedures: Chemistry
Nuclear magnetic resonance spectra CH NMR, laC NMR) were determined on a Bruker AM-300 spectrometer using Me4Si as an internal standard CH NMR). The assignment of all exchangeable protons (OH, NH) was confirmed by the addition of 0 20. laC NMR spectra were acquired using the J modulated spin echo technique where methyl and methirie carbon resonances appear as positive peaks, and methylene and quaternary carbons appear as negative peaks. Silica gel column chromatography was carried out using Merck 7734 silica gel (100-200 urn particle size). EDU was purchased from the Sigma Chemical Company, Missisanga, Canada. (+)-Trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-2'-deoxy-uridine (2) and [4_ l 4C]-2 were prepared using the previously reported procedure (Cheraghali et sl., 1994b) . Trans-(5R,6R) - 5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-5'-0-valeryl-2'-deoxyuridine (3) and (+)-trans-(5R,6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-3',5'-di-0-valeryl-2'-deoxyuridine (4). Valeryl chloride (0.6 mL, 0.5 mrnol) was added to a solution of (+)-trans-(5R, 6R)-5-bromo-5-ethyl-6-ethoxy-5,6-dihYdro-2'deoxyuridine (2) (1.1 g, 2.9 mmol) in dry pyridine (50 mL) at 25°C. The reaction mixture was stirred for 18 h at 25°C. Removal of the solvent in vacuo and purification of the residue obtained by separation on a silica gel column using chloroformmethanol ( 18-4.23 (rn, 1H, H-4'), 4.25-4.40 (m, 2H, H-5'), 4.90 (s, 1H, H-6), 5.14-5.20 (rn, 1H, H-3') , 6.18 (t, J l'2' = J l, 2"= 6.0 Hz, 1H, H-1'), 7.58 (s, 1H, NH); laC NMR (CDCl a) 8 8.37 (CH 2CHa), 13.64 (CH a(CH2hCO), 15.08 (OCH 2CHa), 22.23 (CH aCH2CH2CH2CO), 27.07 and 26.88 (CH 2CHa and CH aCH2CH2CH2CO), 33.86 (CH aCH2CH2CH2CO), 36.69 (C-2'),60.10 (C-5), 63.73 (C-5'), 66.06 (OCH 2CHa), 73.79 (C-3'), 81.54 (C-6), 83.13 (C-1'), 84.69 (C-4'), 150.23 (C-2 C=O), 167.09 173.11 and 173.33 (CH a(CH2hCO) . Anal. Calc. for C2aHa7BrN20a: C, 50.27; H, 6.78; N, 5.09. Found: C, 50.06; H, 7.08; N, 5.11. Further elution of the column with the Same solvent yielded 3 (750 mg, 55%) as a viscous syrup. , 4H, 4.96 (s, 1H, 6.12 (t, J l'.2, =Jl .. 2 , , = 6 .0Hz, 1H, H-1'), 7.80 (s, 1H NH); laC NMR (CDaOD) 8 8.95 (CH 2CHa), 14.04 (CH a(CH2hCO), 15.50 (OCH 2CHa), 23.27 (CH aCH2CH2CH2CO), 28.15 and 28.32 (CH 2CHa and CH aCH2CH2CH2CO), 34.79 (CH aCH2CH2CH2CO), 40.36 (C-2'), 61.44 (C-5), 65.27 (C-5'), 67.06 (OCH 2CHa), 72.15 (C-3'), 174.92 (CHiCH2hCO). Anal. Calc. for ClaH29BrN207: C, 46.45; H, 6.28; N, 6.02. Found: C, 46.85; H, 6.11; N, 5.88. [4-l 4C]-EDU and C 4 C]-2 were synthesized in high specific activity [2 GBq (54 mCi)/mmol] by literature methods (Mercer et al., 1986 and Cheraghali et al., 1994b, respectively) .
[4-l4C]_(+)-Trans-(5R ,6R)-5- bromo-5-ethyl-6-ethoxy-5,6dihydro-5'-0-valeryl-2'-deoxyuridine ([4-l4C] _(3) and [4-l4C]_ (+)-Trans-(5R,6R)- 5-bromo-5-ethyl-6-ethoxy-5,6-dihydro-3',5'di-0-valeryl-2'-deoxyuridine ([4_ l 4C] _(4) were prepared by the addition of valeryl chloride and triethylamine to a solution of [4-l4C]_2 [5.8 MBq (157 /-lCi), specific activity 2 GBq (54 mCi)/mmol] in dichloromethane, followed by work-up essentially as described for non-labelled 2 and 3 (above), and purified by reverse phase preparative HPLC using water:acetonitrile (30:70, vlv) as eluent. [4_ l 4C]-(5R,6R)-3, [4.6 MBq (124 /-lCi), 79% chemical and radiochemical yield, > 96% radiochemical purity, specific activity 2 GBq (54 mCi)/mmol] and [4-l4C]_4, [5.6 MBq (151 /-lCi), 64% chemical and radiochemical yield, >98% radiochemical purity, specific activity 2 GBq (54 mCi)/mmol] were obtained from separate reactions, the latter with a 2 molar excess of esterification reagents.
The [4-l 4C]-labelled diastereomers 3 and 4 were characterized by comparison of their TLC R I values and HPLC retention times on a reverse-phase column, with those of the corresponding authentic unlabelled compound. Specific activities were determined by scintillation counting of a pre-determined amount of each radiolabelled compound.
Biotransformation and biodistribution studies were performed according to the Canadian Council on Animal Care guidelines, with review and approval of protocols by the University of Alberta Health Sciences Animal Welfare Committee. Male Balb/c mice (20-22 g) were purchased from the University of Alberta Health Science Sm?" Animal Services Facility. Three animals were used in each experiment.
The biotransformations of EDU, 2 and 3 were investigated in mice after l.v, injection of a 0.4 mmol/kg dose [0.1 mL of water:polyethylene glycol 400 (40:60, vlv)] of the test compound into the tail vein. Animals were asphyxiated in carbon dioxide at 2, 5, 10, 20, 30, 60, 90 and 120 min intervals after injection of the test compound, and blood samples (about 0.7 mL) were collected immediately, via heart puncture. Each blood sample was extracted by shaking (15 min) the whole blood sample with methanol (2 mL), using a mechanical shaker. This mixture was centrifuged (10 min at 1000 x g) and the resulting supernatant fraction was filtered through a Sep-Pak™ (C18, Waters Millipore) cartridge. Each Sep-Pakt cartridge was preconditioned by washing with methanol (3 mL). The filtrate from the supernatant was dried under a stream of nitrogen gas and the residue obtained was dissolved in methanol (400 ul.), Aliquots (40 /-lL) of these solutions were then analysed by HPLC on a Waters Radial-Pak C18 reverse phase cartridge column (10 /-l, 8 mm x 10 em) at 25°C with UV detection at 230 nm. The identity of each compound present in the sample was determined by comparison of its retention time to that of an authentic sample. The concentration of each compound in blood, as a function of time, was plotted using SigmaPlofT M (Jandel Scientific). The pharmacokinetic parame-ters were calculated using the Lagran program (C. Ediss, University of Alberta).
Biodistributions of [4-14C]-EDU, [4_ 14C]_3 and [4_ 14C]-4were determined after injection of the test compound [126 kBq (3.4 IlCi) mixed with 0.2 mmol kg-1 of non-radioactive compound for a final specific activity of 31.5 MBQImmol, dissolved in 100 ul, into the lateral tail vein of mice. Animals were sacrificed at 3, 8, 18, 30, 60, and 120 min after injection and selected tissues, including liver, brain and blood, were immediately excised. Tissue samples (maximum mL of blood and urine) were prepared for combustion and quantitative trapping of [ 14C]-C0 2 by air drying at room temperature for at least three days to ensure quantitative combustion in an OX-300 Harvey Biological Material Oxidizer, Hillsdale, N.J. The C 4 C]-C0 2 produced upon combustion of the radioactive tissue samples was trapped in 15 mL of Carbon-14 Cocktail (Harvey Co., Fullerton, C.A.) and counted using a Beckman LS 9000 liquid scintillation counter.
Biliary excretion studies in rats were performed in anesthetized animals that had catheters inserted in the jugular vein for dosing, and in the common bile duct for bile collection.
In vivo and in vitro anti-HSV activities of EDU, 2 and 3 against several HSV strains in Hela cells, and NMRI mice inoculated intracerebrally with HSV-1 (KOS) or HSV-2 (196), respectively, were tested using methods described previously (De Clercq and Rosenwirth, 1985; De Clercq et al.,1989) .
Enzymatic hyrdolysis by porcine liver esterase (Sigma EC 3.1.1.1; 15.6 mg protein/mL, 185 units/mg of protein) was used to measure the susceptibility of 3 to enzymatic ester hydrolysis. An aliquot (0.4 mL) of the esterase suspension [in 3.2 M (NH 4hS04 solution] was diluted with phosphate buffer (0.6 mL; O.1M; pH 7.0). The hydrolysis reaction was initiated by adding 3 (0.03 mmol) in DMSO:phosphate buffer (0.6 mL; 50:50, vlv) to the enzyme solution which had been previously equilibrated at 37 ac. Samples (0.1 mL) taken after incubation (3, 8, 18 and 35 min) were poured into ice-cold acetonitrile (0.1 mL) to stop the enzymatic reaction. This mixture was placed in an ice bath for 5 min before centrifugation (1500 x g). The supernatant was then filtered through a 0.45 Il HV filter (Waters Millipore) and an aliquot of the filtrate (20 ilL) was analysed by HPLC. A blank sample (without esterase) was used as a control.
Partition coefficients (P) were determined in n-octanol/water using methods described previously (Cheraghali et al., 1994a) .
